Summary:
- Atossa Therapeutics (ATOS, Financial) secures a U.S. patent for its innovative (Z)-endoxifen oral formulations.
- Analysts project a significant upside potential for ATOS with a price target of $6.00.
- The consensus recommendation classifies ATOS as "Outperform".
Atossa Therapeutics (NASDAQ: ATOS) has achieved a significant milestone by obtaining a U.S. patent for its enteric oral formulations of (Z)-endoxifen, a Selective Estrogen Receptor Modulator. This strategic enhancement to Atossa's intellectual property portfolio underscores its commitment to advancing treatments for hormone-dependent breast and reproductive disorders.
Wall Street Analysts' Forecast
According to insights from three Wall Street analysts, Atossa Therapeutics Inc. (ATOS, Financial) has a one-year average price target of $6.00. This optimism is framed by a high estimate of $7.00 and a low of $4.00, suggesting a significant upside potential of 798.61% from its current trading price of $0.67. For more granular details on price forecasts, visit the Atossa Therapeutics Inc (ATOS) Forecast page.
Furthermore, the current consensus from brokerage firms rates Atossa Therapeutics Inc. (ATOS, Financial) at a 2.0 on a scale from 1 to 5. This rating, which corresponds to an "Outperform," highlights the prevailing positive sentiment among analysts, where 1 indicates a Strong Buy and 5 suggests a Sell.
